GHRP-2, CJC-1295 no DAC (Blend)

In the field of neuroendocrine research, the strategic combination of a Growth Hormone-Releasing Hormone (GHRH) analog with a Growth Hormone-Releasing Peptide (GHRP) represents the most physiologically relevant and experimentally powerful model for interrogating the somatotropic axis . The GHRP-2 and CJC-1295 no DAC Blend embodies this synergistic paradigm at its most potent.

CJC-1295 without DAC—the scientifically accurate designation for Modified GRF (1-29) —is a tetrasubstituted, DPP-4-resistant GHRH analog with a carefully calibrated ~30-minute half-life. It provides the physiological GHRH signal that primes the pituitary for GH synthesis and pulsatile release .

GHRP-2 (Pralmorelin, KP-102) is a high-potency hexapeptide GHSR-1a agonist that delivers maximal GH pulse amplification while also suppressing somatostatin tone—effectively removing the endogenous brake on GH secretion .

When combined, these two mechanistically distinct secretagogues produce a GH response that is significantly greater than the sum of their individual effects . This synergy is not merely additive; it is pharmacologically emergent, arising from:

• Pathway crosstalk between Gαs (GHRH) and Gαq (GHRP-2) signaling cascades
• Somatostatin antagonism by GHRP-2
• Differential receptor regulation (GHRH-R vs. GHS-R)
• Integrated transcriptional and exocytotic responses

At Buy Peptides Online USA, we supply this quintessential dual-action blend as a high-purity, GMP-manufactured research reagent. Each constituent undergoes independent High Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) verification prior to precision blending—the only scientifically defensible standard for heterogeneous peptide formulations.

✅ WHAT IS THE GHRP-2, CJC-1295 (NO DAC) BLEND?

This blend unites two mechanistically distinct but functionally synergistic peptide classes into a single, pre-formulated research tool for integrated somatotropic axis investigation.

🔹 Component Breakdown & Mechanistic Rationale

🔬 CJC-1295 without DAC (Modified GRF 1-29)
Nomenclature Clarity: This is not CJC-1295 with DAC. It is Modified GRF (1-29) , a tetrasubstituted analog of Sermorelin (GRF 1-29) . The "no DAC" designation simply confirms the absence of the Drug Affinity Complex. This is the appropriate tool for pulsatile GH research .

Strategic amino acid substitutions—D-Ala², Ala¹⁵, Leu²⁷—confer resistance to dipeptidyl peptidase-4 (DPP-4) degradation, extending bioactive half-life to ~30 minutes (compared to native GRF's 7-minute half-life) .

Critical Distinction: Unlike DAC-conjugated analogs that bind albumin for extended release (half-life ~6-8 days), Mod GRF produces rapid, physiologically relevant GH pulses that closely mimic endogenous male secretory patterns. This is essential for modeling pulsatile GH dynamics and GHRH–GHRP synergy .

Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight: ~3367.95 g/mol
CAS Number: 863288-34-0
Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂

🔬 GHRP-2 (Pralmorelin; KP-102)

GHRP-2 is a synthetic hexapeptide developed through structure-activity optimization of earlier GHRP compounds. Its strategic incorporation of D-amino acids (D-Ala¹, D-2-Nal², D-Phe⁵) confers significant proteolytic resistance, extending its bioactive half-life and enhancing oral/nasal bioavailability compared to all-L peptides .

Key Mechanistic Attributes:

• Potent GH Pulse Amplitude: GHRP-2 is significantly more potent than GHRP-6 and produces a sharper GH peak .
• Somatostatin Antagonism: Suppresses somatostatin receptor subtype 1 and 2 (sst-1, sst-2) mRNA expression, reducing sensitivity to the endogenous GH brake .
• Orexigenic Effect: Significantly stimulates appetite via NPY/AgRP neuron activation—a distinguishing feature from Ipamorelin .
• Cortisol/PRL Profile: Produces modest, dose-dependent elevations in ACTH, cortisol, and prolactin—generally within physiological range at standard doses (≤100 mcg) .
• Anti-Inflammatory Activity: Suppresses TNF-α, IL-6, and NF-κB activation in inflammatory models .

Molecular Formula: C₄₅H₅₅N₉O₆
Molecular Weight: ~817.97 – 818.0 g/mol
CAS Number: 158861-67-7
Sequence: H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂

The Dual-Action Synergy:

CJC-1295 (no DAC) primes the pituitary for GH synthesis and establishes the pulsatile framework via Gαs/cAMP/PKA/CREB signaling. GHRP-2 delivers potent pulse amplitude via Gαq/IP₃/PKC/Ca²⁺ signaling while simultaneously lifting somatostatin-mediated inhibition. The result is a synergistic GH release—often quantified as 2 + 4 = 12—significantly exceeding the sum of individual effects .

🧪 PRODUCT SPECIFICATIONS & TECHNICAL DATA SHEET

Critical Quality Note: This blend comprises two peptides with divergent physicochemical properties: GHRP-2 (hexapeptide, 0.8 kDa) and CJC-1295 no DAC (30-mer, 3.4 kDa). Simultaneous HPLC purity quantitation is analytically invalid due to differential retention times, UV extinction coefficients, and molecular sizes. Therefore, we employ component-wise pre-analytical verification—the gold standard for heterogeneous peptide blends .

📊 Comprehensive Peptide Specifications Table

🔬 VERIFIED QUALITY: THE DUAL SECRETAGOGUE VALIDATION PROTOCOL

Analytical Challenge: CJC-1295 no DAC (30-mer, 3.4 kDa) and GHRP-2 (6-mer, 0.8 kDa) possess dramatically different physicochemical properties, precluding simultaneous HPLC purity assignment .

Our 4-Tier Verification Protocol:

✅ Tier 1: Component Pre-Analysis. Each raw peptide is individually analyzed via reverse-phase HPLC (C18 column, component-optimized gradients) to confirm ≥98% purity. Identity confirmed via ESI-MS or MALDI-TOF MS against reference standards:

• CJC-1295: ~3368 Da
• GHRP-2: ~818 Da

✅ Tier 2: Precision Blending. Components are gravimetrically dispensed in ISO 7 (Class 10,000) cleanroom environments using calibrated micro-balances (±0.01 mg accuracy). Blend ratios verified by dual weighing.

✅ Tier 3: Post-Blend Identity Confirmation. The final blend undergoes MS to confirm the presence and correct molecular weight signatures of both peptides.

✅ Tier 4: Endotoxin & Bioburden. LAL chromogenic assay verification of <0.05 EU/mg—essential for sensitive primary cell culture and in vivo applications.

"In dual-peptide blends spanning disparate molecular weights, component-wise pre-validation with full analytical traceability is the only scientifically defensible quality standard." — Adapted from pharmacopeial guidelines for complex peptide formulations .

🧬 MECHANISM OF ACTION: How Does This Blend Work?

The GHRP-2 + CJC-1295 no DAC blend models the complete physiological regulation of GH secretion through two convergent but distinct signaling pathways.

📡 GHRH Pathway (CJC-1295 no DAC)

1. GHRH-R Binding: CJC-1295 binds specifically to GHRH receptors on pituitary somatotrophs.
2. G Protein Activation: Activates Gαs, stimulating adenylyl cyclase.
3. cAMP Generation: ATP converted to cyclic AMP (cAMP) , the primary second messenger.
4. PKA Activation: cAMP activates protein kinase A (PKA) .
5. CREB Phosphorylation: PKA phosphorylates transcription factor CREB at Ser133.
6. Gene Transcription: Phospho-CREB binds cAMP response elements (CRE) in the GH gene promoter, stimulating GH synthesis and exocytosis .

📡 GHRP Pathway (GHRP-2)

1. GHSR-1a Binding: GHRP-2 binds specifically to ghrelin receptors (GHSR-1a) on pituitary and hypothalamic neurons.
2. G Protein Activation: Primarily activates Gαq, stimulating phospholipase C (PLC) .
3. IP₃/DAG Generation: PLC hydrolyzes PIP₂ to generate inositol trisphosphate (IP₃) and diacylglycerol (DAG) .
4. Calcium Mobilization: IP₃ triggers Ca²⁺ release from ER stores.
5. PKC Activation: DAG activates protein kinase C (PKC) .
6. GH Exocytosis: Elevated intracellular Ca²⁺ and PKC activation trigger fusion of GH vesicles .
7. Somatostatin Antagonism: GHRP-2 suppresses sst-1 and sst-2 mRNA expression, reducing sensitivity to the inhibitory hormone somatostatin .

🔄 Pathway Crosstalk: The Synergy Mechanism

The synergistic GH release (2+4=12) arises from intracellular signal integration:

• In cells with pre-activated adenylyl cyclase (CJC-1295 signal), the PKC pathway (GHRP-2 signal) potentiates cAMP production .
• GHRP-2 upregulates GHRH-R expression at low doses, priming cells for GHRH response .
• CJC-1295 upregulation of GH synthesis provides more available hormone for GHRP-2-triggered exocytosis .
• GHRP-2 removes somatostatin inhibition, allowing the CJC-1295 signal to proceed unimpeded .

🧬 PRIMARY RESEARCH APPLICATIONS & TYPICAL RESEARCH FOCUSES

This blend is designed exclusively for controlled laboratory investigations. Below are the predominant domains of preclinical inquiry, synthesized from peer-reviewed literature .

1. 📈 Somatotropic Axis & GH Pulsatility Research

Primary Function/Purpose: Growth Hormone Support, Neuroendocrine Research, Pulsatility Modeling
Key Focus: GHRH–GHSR pathway integration, pulse amplitude/frequency modulation, receptor regulation.

• Synergistic GH Release: Combined GHRH + GHRP produces GH release significantly exceeding the sum of individual effects. This is the benchmark positive control for all GHRH–GHRP interaction studies .
• Pulse Amplitude Modeling: GHRP-2 provides maximal pulse amplitude, while CJC-1295 no DAC provides the physiological pulsatile framework—essential for modeling male GH secretory patterns .
• Receptor Regulation: Low-dose GHRP-2 increases GHS-R mRNA levels; high-dose or prolonged exposure can downregulate both GHRH-R and GHS-R, modeling receptor desensitization .
• Documented IGF-1 Elevation: Independent researcher bloodwork (n=1, age 52) demonstrated IGF-1 increase from 227 ng/mL to 406 ng/mL (79% increase) using 100mcg Mod GRF + 100mcg GHRP-2 (or equivalent GHRP) administered 3x daily .
• Research Model: Primary rat/ovine pituitary cell culture; GH3 somatotroph cell line; serial tail-vein blood sampling with GH-ELISA; cAMP/PKC pathway inhibitor studies.

2. 🧠 Appetite & Energy Homeostasis Research

Primary Function/Purpose: Weight Management, Metabolic Research, Obesity Studies
Key Focus: Orexigenic signaling, ghrelin receptor pharmacology, NPY/AgRP neurons.

• GHRP-2 Component: Provides significant, measurable orexigenic signaling via NPY/AgRP neuron activation—distinct from Ipamorelin .
• CJC-1295 Component: Provides GH-mediated metabolic effects (lipolysis, nitrogen retention) without appetite confounds.
• Research Application: Enables researchers to dissect GH-dependent vs. appetite-dependent metabolic changes.
• Research Model: DIO rodent models; metabolic cage studies; NPY/AgRP neuron calcium imaging; pair-feeding paradigms.

3. 🔬 Anti-Inflammatory & Immunomodulatory Research

Primary Function/Purpose: Immune Support, Anti-Inflammatory, Cytokine Research
Key Focus: NF-κB suppression, acute lung injury, arthritis models.

• GHRP-2 Component: Suppresses TNF-α and IL-6; inhibits NF-κB activation; reduces superoxide anions and lipoxygenase .
• CJC-1295 Component: May contribute indirect immunomodulation via GH/IGF-1 axis.
• Research Model: LPS-stimulated macrophages; acute lung injury rodent models; collagen-induced arthritis; ELISA cytokine arrays.

4. 🧪 Sleep & Chronobiology Research

Primary Function/Purpose: Cognitive Function, Sleep Research
Key Focus: NREM sleep, GHRHergic neuron activity.

• CJC-1295 Component: As a GHRH agonist, stimulates hypothalamic neurons promoting NREM deep sleep .
• GHRP-2 Component: GH pulse amplification correlates with increased NREMS duration.
• Research Model: Rodent EEG/EMG sleep recording; hypothalamic slice electrophysiology; circadian gene expression profiling.

5. 🦴 Skeletal & Connective Tissue Research

Primary Function/Purpose: Recovery & Healing, Musculoskeletal Research
Key Focus: Osteoblast proliferation, fracture healing, collagen synthesis.

• GH/IGF-1 axis activation stimulates osteoblast differentiation and collagen matrix deposition.
• Research Model: Ovariectomized (OVX) osteoporosis models; micro-CT analysis; osteoblast alkaline phosphatase assays.

6. 🧬 ACTH, Prolactin & Cortisol Pharmacology

Primary Function/Purpose: Endocrine Research, Pituitary Hormone Interactions
Key Focus: Off-target endocrine effects, dose-response characterization.

• GHRP-2 Component: At saturation dose (100 mcg) , produces small, transient increases in prolactin and cortisol. These are generally within physiological range but are measurable—making GHRP-2 the appropriate tool when these endpoints are of interest .
• CJC-1295 Component: Does not directly stimulate ACTH or prolactin release .
• Research Application: Comparator molecule for studies investigating GHSR-1a selectivity and biased agonism.

❄️ HANDLING, STORAGE & RECONSTITUTION PROTOCOL

Critical Note: Both peptides are stable when lyophilized and stored frozen. Reconstituted solutions should not be frozen and should be used within 28 days .

🧊 Storage Integrity Protocol

💧 Standardized Reconstitution Protocol (4mg Total Mass)

Based on validated laboratory protocols for 2mg CJC-1295 no DAC + 2mg GHRP-2 :

1. Equilibration: Allow vial to reach room temperature in a desiccated environment (15-20 minutes) to prevent moisture condensation.
2. Solvent Selection: Use Bacteriostatic Water (0.9% Benzyl Alcohol) for multi-use studies.
3. Volume Calculation: Inject 2.0 mL of solvent.
   • Final Concentration: 2.0 mg/mL total peptide.
   • Component Concentrations: 1.0 mg/mL each (CJC-1295 and GHRP-2).
4. Technique: Insert syringe at 45° angle. Direct fluid slowly against the inner vial wall. Do NOT shake. Gently swirl or roll for 60 seconds.
5. Visual Inspection: Solution should be clear and colorless. Discard if particulate matter present.

📊 Syringe Measurement Reference (U-100 Insulin Syringe)

At 2.0 mL reconstitution volume (1.0 mg/mL concentration per component) :

⏱️ Research Dosing Frequency Guidance

For chronic studies modeling physiological male GH pulsatility, established protocols employ:

• Frequency: 2-3x daily (e.g., 0800, 1400, 2000) .
• Interval: Minimum 3-4 hours between administrations to allow receptor recovery and prevent desensitization .
• Route: Subcutaneous (SC) injection .

❓ FREQUENTLY ASKED QUESTIONS (FAQ)

Q: What is the definitive difference between this blend (CJC no DAC + GHRP-2) and the CJC no DAC + Ipamorelin blend?

A: This is a critical experimental design choice.

Choose GHRP-2 blend when your research question requires maximal GH pulse amplitude and either appetite/orexigenic signaling is part of your study, or modest prolactin/cortisol elevation is not a confound. Choose Ipamorelin blend when you need clean GH data without appetite or endocrine confounds .

Q: Why is CJC-1295 "no DAC" specified? What about "with DAC"?

A: Critical distinction.

• CJC-1295 with DAC = GRF 1-29 + Drug Affinity Complex (succinimidyl group). Half-life: ~6-8 days. Produces sustained, non-pulsatile GH bleed (female pattern). Not appropriate for modeling male GH pulsatility.
• CJC-1295 without DAC (Mod GRF 1-29) = Tetrasubstituted GRF 1-29 analog. Half-life: ~30 minutes. Produces physiological, pulsatile GH release (male pattern). Essential for GHRH–GHRP synergy studies.
  Our blend contains Mod GRF (no DAC).

Q: What is the saturation dose for this blend?

A: The saturation dose (dose at which GH release plateaus) is 100 mcg each per pulse (total 200 mcg blend). Doses above this produce diminishing returns in GH release but increasing off-target effects (prolactin, cortisol from GHRP-2) .

Q: Does this blend cause desensitization with repeated administration?

A: Low doses (≤100 mcg each) administered 3x daily show low desensitization risk. High doses (≥200 mcg each) or continuous exposure can downregulate both GHRH-R and GHS-R mRNA. If desensitization occurs, a 3-7 day washout typically restores sensitivity .

Q: Can the components be used separately?

A: Yes, but the purpose of the blend is convenience and consistency. Pre-formulated at a precise 1:1 ratio, it eliminates pipetting errors and ensures every research subject receives the exact same ratio—reducing experimental variables .

Q: What is the expected IGF-1 elevation with this blend?

A: Independent bloodwork (n=1, age 52) using a similar GHRH+GHRP protocol demonstrated IGF-1 increase from 227 ng/mL to 406 ng/mL (79% increase) after 2 weeks of 3x daily administration. This elevated IGF-1 to levels exceeding the average 18-year-old reference range (116-358 ng/mL) .

Q: Do you provide medical dosage instructions?

A: Absolutely not. As a Research Use Only (RUO) supplier, we strictly prohibit providing medical or veterinary instructions. Determining the appropriate dose, concentration, and administration route for your specific IACUC-approved protocol is the sole responsibility of the qualified Principal Investigator (PI).

🧬 PEPTIDE STRUCTURE & STABILITY INSIGHTS

Why "no DAC" Matters in CJC-1295:
The Drug Affinity Complex (DAC) is a reactive succinimidyl ester moiety that covalently conjugates to lysine residues on serum albumin. CJC-1295 without DAC completely lacks this modification. It is not a "truncated" or "inferior" version—it is a mechanistically distinct research tool engineered specifically for pulsatile, non-continuous GHRH receptor activation. The four strategic substitutions (D-Ala², Ala¹⁵, Leu²⁷) provide DPP-4 resistance while preserving the 30-minute pulse window essential for modeling male GH secretory patterns .

Strategic D-Amino Acids in GHRP-2:
GHRP-2 contains three D-amino acids (D-Ala¹, D-2-Nal², D-Phe⁵). This confers:

• Resistance to proteolytic cleavage by exopeptidases
• Extended bioactive half-life compared to all-L peptides
• Enhanced receptor binding affinity (D-2-Nal² engages hydrophobic receptor pocket)

The Critical Role of D-2-Nal²:
D-2-Naphthylalanine is a non-natural amino acid with a bulky naphthalene side chain. This modification is essential for high-affinity GHSR-1a binding. The naphthalene ring engages in hydrophobic stacking interactions with aromatic residues in the receptor's transmembrane binding pocket .

C-Terminal Amidation (-NH₂):
Both peptides feature C-terminal amidation. This neutralizes the negative charge of the terminal carboxyl group, improving receptor recognition and proteolytic stability by blocking carboxypeptidase cleavage.

🚀 WHY PURCHASE GHRP-2, CJC-1295 (NO DAC) BLEND FROM BUY PEPTIDES ONLINE USA?

The peptide supply landscape is heterogeneous. We differentiate through methodological transparency and researcher-first logistics.

✅ Component-Verified Purity: Each constituent is tested individually (≥98% HPLC/MS) prior to precision blending—essential for heterogeneous blends where simultaneous HPLC is analytically invalid .
✅ Accurate Nomenclature: We label correctly. Mod GRF 1-29 (CJC no DAC) . CAS 863288-34-0. No confusion with DAC variants. GHRP-2 . CAS 158861-67-7.
✅ Third-Party Transparency: Independent COA documentation per batch—no proprietary secrecy. Full analytical traceability.
✅ GMP-Ancillary Manufacturing: Produced in ISO 9001-aligned facilities; rigorous environmental monitoring and documentation.
✅ Low Endotoxin: <0.05 EU/mg—suitable for sensitive primary cell culture and in vivo work.
✅ Cold-Chain Packaging: Lyophilized peptides shipped with temperature-indicating desiccants and insulated containers.
✅ Authenticity Guarantee: Full replacement or refund if product fails independent verification of stated specifications.
✅ Secure Crypto Payments: Bitcoin, Ethereum, USDT accepted for discreet, frictionless transactions.
✅ 24/7 Technical Support: Protocol consultation regarding reconstitution, solubility, and handling (RUO context only).
✅ USA-Based Operations: Rapid fulfillment from domestic distribution hubs. Free shipping on orders over $300.
✅ Bulk Availability: Volume discounts for institutional laboratories (contact for custom quotas).

📦 PACKAGING & DELIVERY INTELLIGENCE

• Primary Container: Sterile, crimp-sealed Type I borosilicate glass vial.
• Fill Strength: 4mg total mass (2mg CJC-1295 no DAC / 2mg GHRP-2).
• Protection: Foil pouch with integrated desiccant; anti-static cushioning.
• Discretion: Plain, non-descript outer carton.
• Lead Time: Orders processed within 1-2 business days. USA delivery: 2-5 business days.
• International: Worldwide shipping available, subject to local import/export compliance.

⚖️ LEGAL & COMPLIANCE DISCLAIMER

STRICT RESEARCH USE ONLY (RUO).

• NOT FOR HUMAN OR VETERINARY CONSUMPTION.
• NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.
• NOT FDA APPROVED.

This product is intended solely for in vitro or animal model research by qualified professionals in a controlled laboratory setting. GHRP-2 and growth hormone secretagogues are prohibited substances in competitive sports under WADA regulations. Researchers must ensure compliance with all applicable institutional, local, state, and federal regulations.

All product information, including proposed mechanisms and applications, is derived from peer-reviewed literature and is presented for educational purposes only. It does not constitute medical advice or a claim regarding the treatment or cure of any disease or condition .

By purchasing, the buyer confirms compliance with all applicable regulations and institutional oversight.

⭐ RESEARCHER INSIGHTS

Synthesized feedback from our institutional and private research clientele:

🔹 "We specifically needed the GHRP-2 version for its orexigenic effect—our study requires appetite stimulation as a positive control. The blend saves us from reconstituting two separate vials." — Ph.D., Metabolic Research
🔹 "The COA included pre-blend HPLC traces for both components. CJC-1295 at 3368 Da and GHRP-2 at 818 Da. This is exactly what we need for our methods section." — Lead Scientist, Neuroendocrinology
🔹 "Consistent GH release in our rat model. Peak at 15-20 minutes as expected. Vial arrived intact with desiccant." — Verified Buyer
🔹 "Accurate labeling—'no DAC' confirmed via MS. Many suppliers conflate Mod GRF with DAC version. Thank you for the precision." — Principal Investigator, Animal Science
🔹 "Crypto checkout was seamless. Shipping to the East Coast took 3 days. Will reorder for our next study cohort." — Verified Buyer

💼 SERVICE ECOSYSTEM

• 24/7 Support: Live chat and email response for urgent research inquiries.
• Product Replacement: Transparent, no-hassle policy for compromised vials.
• Authenticity Guarantee: Backed by verifiable, shareable analytical data.
• Technical Consultation: Educational guidance on standard peptide handling and reconstitution.
• Complaint Handling: Direct escalation pathway to Quality Assurance.

Catalog Reference: GHRP2-CJC-BLEND-4MG
Composition: GHRP-2 (Pralmorelin) (2mg) | CJC-1295 no DAC (Mod GRF 1-29) (2mg)
Total Mass: 4mg per vial
Form: Lyophilized Powder (White to off-white cake)
Purity: ≥98% (Component-Verified, HPLC/MS)
Endotoxin: <0.05 EU/mg
Storage: Freeze at -20°C immediately upon receipt
Stability: 24 months (lyophilized, -20°C, desiccated, light-protected)
Status: In Stock — Ready for Immediate Dispatch

🚀 Advance from additive to synergistic GH pulse modeling. Add the GHRP-2, CJC-1295 no DAC Blend to your laboratory requisition cart now.